Literature DB >> 17074853

Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection.

Anthony A Ryan1, Joanne M Spratt, Warwick J Britton, James A Triccas.   

Abstract

A strain of Mycobacterium bovis BCG that secretes high levels of functional murine monocyte chemotactic protein 3 (BCG(MCP-3)) was developed. Mice vaccinated with BCG(MCP-3) displayed increased lymphocyte migration in vivo and augmented antigen-specific T-cell responses compared to mice vaccinated with BCG alone. The level of protection afforded by BCG(MCP-3) was equivalent to that with control BCG; however, immunodeficient mice infected with BCG(MCP-3) survived significantly longer than mice infected with the control BCG strain. Therefore, BCG(MCP-3) may be a safer alternative than conventional BCG for vaccination of immunocompromised individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074853      PMCID: PMC1828426          DOI: 10.1128/IAI.00897-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  Adhesion mechanisms regulating the migration of monocytes.

Authors:  Beat A Imhof; Michel Aurrand-Lions
Journal:  Nat Rev Immunol       Date:  2004-06       Impact factor: 53.106

3.  Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis.

Authors:  W Peters; H M Scott; H F Chambers; J L Flynn; I F Charo; J D Ernst
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection.

Authors:  Bernadette M Saunders; Stephen Tran; Sigrid Ruuls; Jonathon D Sedgwick; Helen Briscoe; Warwick J Britton
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

5.  The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol.

Authors:  A Rainczuk; P M Smooker; L Kedzierski; C G Black; R L Coppel; T W Spithill
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

6.  Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis.

Authors:  Umaimainthan Palendira; Arun T Kamath; Carl G Feng; Ela Martin; Paul J Chaplin; James A Triccas; Warwick J Britton
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

7.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Authors:  Y Luo; H Yamada; X Chen; A A Ryan; D P Evanoff; J A Triccas; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

8.  Identification of strong promoter elements of Mycobacterium smegmatis and their utility for foreign gene expression in mycobacteria.

Authors:  Joanne M Spratt; Warwick J Britton; James A Triccas
Journal:  FEMS Microbiol Lett       Date:  2003-07-15       Impact factor: 2.742

9.  Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.

Authors:  Alexander S Pym; Priscille Brodin; Laleh Majlessi; Roland Brosch; Caroline Demangel; Ann Williams; Karen E Griffiths; Gilles Marchal; Claude Leclerc; Stewart T Cole
Journal:  Nat Med       Date:  2003-04-14       Impact factor: 53.440

10.  Incorporation of CpG oligodeoxynucleotide fails to enhance the protective efficacy of a subunit vaccine against Mycobacterium tuberculosis.

Authors:  Meng-Jer Hsieh; Ana-Paula Junqueira-Kipnis; A Hoeffer; Oliver C Turner; Ian M Orme
Journal:  Vaccine       Date:  2004-01-26       Impact factor: 3.641

View more
  9 in total

Review 1.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

Review 2.  Recombinant BCG as a vaccine vehicle to protect against tuberculosis.

Authors:  James A Triccas
Journal:  Bioeng Bugs       Date:  2009-11-02

Review 3.  Recombinant BCG to Enhance Its Immunomodulatory Activities.

Authors:  Magdalena Kowalewicz-Kulbat; Camille Locht
Journal:  Vaccines (Basel)       Date:  2022-05-23

4.  Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.

Authors:  James A Triccas; Elena Shklovskaya; Joanne Spratt; Anthony A Ryan; Umaimainthan Palendira; Barbara Fazekas de St Groth; Warwick J Britton
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

Review 5.  Applications of chemokines as adjuvants for vaccine immunotherapy.

Authors:  Teena Mohan; Wandi Zhu; Ye Wang; Bao-Zhong Wang
Journal:  Immunobiology       Date:  2017-12-08       Impact factor: 3.144

Review 6.  Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.

Authors:  Yi Luo; Jonathan Henning; Michael A O'Donnell
Journal:  Clin Dev Immunol       Date:  2011-09-15

7.  Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa.

Authors:  Santhuri Rambaran; Kogieleum Naidoo; Lara Lewis; Razia Hassan-Moosa; Dhineshree Govender; Natasha Samsunder; Thomas J Scriba; Nesri Padayatchi; Aida Sivro
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

Review 8.  A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19.

Authors:  Shivani Singh; Noemi Alejandra Saavedra-Avila; Sangeeta Tiwari; Steven A Porcelli
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

Review 9.  Next-Generation Vaccines Based on Bacille Calmette-Guérin.

Authors:  Natalie E Nieuwenhuizen; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2018-02-05       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.